Mixed Signals From Trials of Perioperative, Neoadjuvant Immunotherapy for Early TNBC

(MedPage Today) -- SAN ANTONIO -- Two trials of neoadjuvant immunotherapy for triple-negative breast cancer (TNBC) produced mixed efficacy signals.
The NSABP B-59/GBG-96-GeparDouze trial showed that adding perioperative atezolizumab (Tecentriq...